# Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer

> **NCT01212822** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Adenocarcinoma of the Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Diffuse Adenocarcinoma of the Stomach
- Intestinal Adenocarcinoma of the Stomach
- Mixed Adenocarcinoma of the Stomach
- Squamous Cell Carcinoma of the Esophagus
- Stage IA Esophageal Cancer
- Stage IA Gastric Cancer
- Stage IB Esophageal Cancer
- Stage IB Gastric Cancer
- Stage IIA Esophageal Cancer
- Stage IIA Gastric Cancer
- Stage IIB Esophageal Cancer
- Stage IIB Gastric Cancer
- Stage IIIA Esophageal Cancer
- Stage IIIA Gastric Cancer
- Stage IIIB Esophageal Cancer
- Stage IIIB Gastric Cancer
- Stage IIIC Esophageal Cancer
- Stage IIIC Gastric Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** oxaliplatin
- **DRUG:** leucovorin calcium
- **DRUG:** fluorouracil
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01212822
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-27
- **Primary completion:** 2014-10-24
- **Final completion:** 2018-01-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212822, "Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01212822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*